Esperion Therapeutics, Inc. (ESPR): Price and Financial Metrics

Esperion Therapeutics, Inc. (ESPR): $2.14

0.17 (-7.36%)

POWR Rating

Component Grades








Add ESPR to Watchlist
Sign Up

Industry: Biotech




#78 of 360

in industry

ESPR Price/Volume Stats

Current price $2.14 52-week high $3.40
Prev. close $2.31 52-week low $0.70
Day low $2.04 Volume 7,547,000
Day high $2.42 Avg. volume 6,866,144
50-day MA $2.51 Dividend yield N/A
200-day MA $1.77 Market Cap 396.01M

ESPR Stock Price Chart Interactive Chart >

Esperion Therapeutics, Inc. (ESPR) Company Bio

Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company was founded in 1998 and is based in Ann Arbor, Michigan.

ESPR Latest News Stream

Event/Time News Detail
Loading, please wait...

ESPR Latest Social Stream

Loading social stream, please wait...

View Full ESPR Social Stream

Latest ESPR News From Around the Web

Below are the latest news stories about ESPERION THERAPEUTICS INC that investors may wish to consider to help them evaluate ESPR as an investment opportunity.

Esperion to Participate in 42nd Annual J.P. Morgan Healthcare Conference

ANN ARBOR, Mich., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 42nd Annual J.P. Morgan Healthcare Conference. Sheldon Koenig, President and CEO, will deliver a corporate presentation on Wednesday, January 10, 2024, at 2:15 PM PT (5:15 PM ET). The Esperion management team will also be hosting investor meetings during the conference. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investor and med

Yahoo | December 18, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning!

William White on InvestorPlace | December 14, 2023

U.S. FDA Updates LDL-C Lowering Indication for Esperion’s NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet

– Updated Label Adds Primary Hyperlipidemia, Removes Maximally Tolerated Statin Requirement, Removes Limitation of Use – – Cardiovascular (CV) Risk Reduction Labels Remain on Track: in U.S. with PDUFA Date of March 31; in Europe with Anticipated Approval in 1H 2024 – ANN ARBOR, Mich., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the U.S. Food and Drug Administration (FDA) has approved an updated LDL-cholesterol lowering indication for NEXLETOL and NEXLIZET to in

Yahoo | December 13, 2023

Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 8, 2023

Why Is Esperion Therapeutics (ESPR) Up 51.4% Since Last Earnings Report?

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | December 7, 2023

Read More 'ESPR' Stories Here

ESPR Price Returns

1-mo 3.38%
3-mo N/A
6-mo 127.15%
1-year 71.20%
3-year -92.09%
5-year -94.86%
YTD -28.43%
2023 -52.01%
2022 24.60%
2021 -80.77%
2020 -56.40%
2019 29.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!